Skip to main content

Advertisement

Table 3 Outcomes of other efficacy endpoints investigated in the meta-analysis in the overall population and in the normal and poor response subgroups (difference between r-hFSH plus r-hLH and r-hFSH alone groups; ITT population)

From: Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis

  Mean difference/RR (95% CI) between r-hFSH plus r-hLH and r-hFSH groups
  Overall ITT population Poor responders Normal responders
Number of metaphase II oocytes 0.02 (−0.29 to 0.33)a 0.69 (0.12 to 1.25)a −0.28 (−0.66 to 0.10)a
Number of embryos 0.09 (−0.11 to 0.30)a 0.34 (−0.05 to 0.73)a −0.01 (−0.27 to 0.25)a
Number of transferred embryos 0.09 (0.01 to 0.17)a 0.27 (0.07 to 0.47)a 0.05 (−0.05 to 0.15)a
Number of good quality embryos 0.26 (0.16 to 0.36)a 0.43 (0.26 to 0.06)a 0.17 (0.05 to 0.29)a
Peak oestradiol (ng/L) 0.24 (0.06 to 0.42)a 0.21 (−0.12 to 0.54)a 0.26 (0.03 to 0.48)a
Duration of ovarian stimulation (days) −0.23 (−0.50 to 0.05)a −0.51 (−1.15 to 0.12)a −0.15 (−0.49 to 0.18)a
Total r-hFSH dose (IU/1000) −0.11 (−0.22 to 0.00)a −0.38 (−0.59 to −0.17)a −0.06 (−0.16 to 0.04)a
Biochemical pregnancy rate 1.25 (1.13 to 1.38)b 1.38 (1.06 to 1.80)b 1.22 (1.04 to 1.42)b
Ongoing pregnancy rate 1.14 (1.05 to 1.25)b 1.36 (1.04 to 1.79)b 1.13 (1.00 to 1.27)b
Live birth rate 1.11 (1.01 to 1.21)b 1.30 (0.95 to 1.78)b 1.10 (0.94 to 1.29)b
  1. aMean difference (95% CI).
  2. bRR (95% CI).
  3. CI, confidence interval; ITT, intention-to-treat; r-hFSH, recombinant human follicle-stimulating hormone; r-hLH, recombinant human luteinizing hormone; RR, risk ratio.
  4. Note: bold denotes statistical significance for r-hFSH plus r-hLH versus r-hFSH alone.